2 Available data support a role for inhibition of SR-PDE in both positive inotropy and vasodilation produced by indolidan.
I ndolidan (LY195115), a dihydropyridazinoqe
cardiotonic, produces potent positive inotropic and vasodilatory effects of long duration in vivo 1 and is currently undergoing clinical evaluation for treatment of congestive heart failure. This cornpound is a potent, selective, and competitive inhibitor of cyclic AMP (cAMP) phosphodiesterase (PDE) located in sarcoplasmic reticulum membranes (i.e., SR-PDE).
2 Available data support a role for inhibition of SR-PDE in both positive inotropy and vasodilation produced by indolidan. 2 -3 Based on high affinity for cAMP and lack of stimulation by calmodulin or cyclic GMP (cGMP), ' and milrinone provided preliminary evidence of a role for this site in mediating positive inotropy. 13 The present studies were conducted to characterize the properties of this site, including subcellular location, identity, and pharmacological relevance. Particular emphasis was placed on examining further the role of SR-PDE in mediating positive inotropic effects of indolidan and other cardiotonic PDE inhibitors. A preliminary report on a portion of these findings has appeared in the literature. 14 
Materials and Methods

Isolation of Canine Cardiac Membranes
Highly purified sarcolemmal vesicles were prepared from ventricles of purpose-bred hounds anesthetized with sodium pentobarbital (35 mg/kg i.v.) as described by Jones et al, 13 except that myocardial vesicles were subjected to a total of four 30-second homogenizations with the Polytron apparatus at a setting of 7.5 (PT20ST, Brinkmann Instruments, Westbury, New York). During the preparation of sarcolemmal vesicles, membranes sedimenting at ll,Q00g for 20 minutes were harvested as a source of mitochondrial membranes. 16 Myocardial vesicles (Procedure 1) and subtractions of SR vesicles (fractions A through E) were isolated from canine ventricles as described. 17 Fraction A contained relatively pure sarcolemmal membranes, although SR contamination was greater than in the SLV preparation described above. Fractions B, C, and D are considered to be derived from junctional SR, while fraction E originates from free SR. 18 Aliquots of the various membrane fractions were stored frozen at -80° C in 0.25 M sucrose, 10 mM histidine, pH 7.5, for up to 3 months with no detectable changes in properties of the binding site described below. Vesicle protein was determined by the BCA protein assay 19 using bovine serum albumin (BSA; fraction V) as the protein standard.
Determination of Enzyme Activities
Cyclic nucleotide PDE activity of myocardial vesicles was determined at 1 j/M cAMP by the two-step method essentially as described by Thompson et al. 6 Reactions were carried out in 30 mM Tris/Cl, pH 8.0, 0.1 mM dithiothreitol, 5 mM MgCl 2 , and 1 jiM [ In certain experiments the concentration and identity of divalent metal cations included in the reaction medium were varied ( Figure 12 ). PDE reactions were initiated by adding sufficient enzyme to hydroryze less than 20% of the substrate in 60 minutes at room temperature (22 ±2° C). Reactions were terminated by placing tubes in boiling water for 45 seconds. PDE activity was linear versus time and protein concentration (data not shown). Inhibition curves were generated by determining PDE activity in duplicate at 10 inhibitor concentrations (5 log units) spanning the IQo (concentration at which 50% inhibition of activity occurred). Dimethyl sulfoxide was used as a solvent for PDE inhibitors. Inhibitor solutions were prepared on the day of an experiment, and controls were run to ensure that carryover solvent (2.5%, vol/vol) had no effect on assay results. Ca 2+ -ATPase activity was quantitated at 37° C by appearance of inorganic phosphate as described previously. 20 Reactions were carried out in 50 mM histidine, pH 7.4, 3 mM MgCl 2 , 3 mM ATP (Na + ), 100 mM KC1, and 50 fjM CaCl 2 . Ca 2+ -ATPase activity was that portion of total activity that was inhibited by 1 mM EGTA/Tris. In the case of mitochondrial membranes, Ca 2+ -ATPase was determined in the presence of 5 mM sodium azide in order to reduce background activity.
Determination of Membrane Binding
Binding studies were routinely carried out at 25° C in 1.0 ml of the following standard medium: 50 mM Tris-Cl, 5 mM MgCl 2 , 0.01% BSA, pH 7.4, in the presence of varying concentrations of [ 3 H]LY186126. Binding reactions were initiated by the addition of membrane vesicles (15-100 fig protein) to the medium and allowed to proceed to completion (60 minutes), at which time the membrane suspension was filtered using a vacuum apparatus (Brandel cell harvestor) onto Whatman GF/C filters pretreated with 50 mM Tris-Cl, 0.05% BSA, pH 7.4, to minimize nonspecific binding. Filters were washed rapidly four times with cold (0-4° C) 50 mM sodium phosphate, pH 7.4. Total radioactivity retained by the filter was determined by scintillation counting filters in 10 ml Beckman Ready Protein + cocktail (Beckman Instruments, Fullerton, California). Specific binding was defined as the portion of total bound radioactivity displaced by 100 ixM indolidan. Binding was determined in triplicate at each concentration of [H]LY186126 unless stated otherwise. When the effect of pH on binding was examined (Figure 2 ), 50 mM histidine was incuded in the standard medium to provide effective buffering down to pH 5.0. In certain experiments, the identity and concentration of the divalent cation included in the binding medium was varied (see "Results").
The time course for dissociation of bound [ 21 and LUNDON software (Lundon Software, Cleveland, Ohio). Correlation coefficients were obtained from linear regression analysis, and statistical significance of linear correlations was assessed as described in the literature. 22 Values of /><0.05 were taken to indicate statistical significance.
Materials
The synthesis and characterization of [ Moreover, this relationship was apparent despite the use of biochemically and functionally distinct subfractions of SR vesicles in this analysis. 18 In a previous communication, [ 3 H]LY186126 binding to SR membranes was shown to be dependent on the presence of MgCl 2 in the medium. 13 The ability of various divalent cations to support binding is examined in Figure 5 . At a fixed concentration of 5 mM divalent cation, the amount of [ Figure 9 . IQo values were obtained from inhibition curves determined at 1 uM cAMP (caffeine and rolipram; data not shown) or from published reports. 2 ever, was not one of identity since the slope of the curve was significantly different from a value of 1.0.
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A subset of the compounds tested in Figure 8 , that is, the positive inotropic PDE inhibitors, was chosen for analyzing the pharmacological relevance of the Figure 6 , there was only a slight (approximately twofold) difference between the Kv alues for indolidan determined in the presence of the two divalent cations ( Figure 11A ). By contrast, the displacement curve for cGMP was shifted 60-fold to the right (K^=0A uM) when Zn 2+ was used in place of Mg , and Zn 2+ to activate cAMP PDE associated with myocardial vesicles was examined, and the results are shown in Figure  12 . In a previous report, it was shown that SR-PDE accounted for approximately 80% of total PDE activity associated with this membrane preparation. 13 In the present report, we demonstrated the presence of an apparently identical binding site ( Figure  1 ) in a less purified membrane preparation (myocardial vesicles). Importantly, additional classes of binding sites were not detected in this membrane preparation. This finding was useful because myocardial vesicles can be obtained more readily and in much greater yield than purified SR vesicles (fraction E) with only a slight (approximately twofold) decrease in [ Binding K d values were furthermore shown to correlate significantly with ED^ values for in vivo positive inotropic effects for a structurally diverse set of positive inotropic agents, all of which are known to be relatively potent inhibitors of SR-PDE. 2 Thus, the results support a role for the high affinity 3H]LY186126 binding site in mediating pharmacological effects of these agents in cardiac tissue. Taken together, our findings support the hypothesis that inhibition of SR-PDE is an important biochemical mechanism underlying direct positive inotropic effects of these compounds. Our data confirm and extend conclusions of others concerning an important role for isozyme-selective PDE inhibition in mediating cardiac effects of these drugs. Although the data suggest that cGMP competes for the same site as the dihydropyridazinones (indolidan and LY186126), the question arose whether or not binding determinants for these two types of ligands were identical. To examine this point, use was made of the fact that Zn 2+ increased the B^ for [ Figure  6 ). If both substrate (cGMP) and inhibitors were bound to an identical site, then Zn 2+ would not be expected to have an effect on the K^ for cGMP. The results in Figure 11 show that Zn 2+ produced a substantial decrease in affinity for cGMP, indicating that binding determinants for this cyclic nucleotide are not identical to those of the dihydropyridazinones. Rather, these two classes of ligands probably interact with some common binding site amino acid residues, possibly at the catalytic site of SR-PDE, while possessing certain distinct binding interactions of their own. Although our data do not support the possibility of strong negative allosteric coupling between two distinct sites for these compounds, they nevertheless do not rule out this alternative explanation.
Because ". In good agreement with the binding data in Figure 5 , Mn 2+ did in fact support an enhanced rate of cAMP hydrolysis relative to Mg 2 + (Figure 12 ). By contrast, however, Zn 2+ completely inhibited PDE activity at concentrations >50 fiM. A further lack of correspondence between binding and PDE activity was seen in the dramatic difference in potencies for activation of these two parameters by Mg 2+ (Figures  7 and 12 ). These data point out the lack of a one to one correspondence between binding and enzyme activity, raising the possibility that the [ binding site is not identical to the catalytic site of SR-PDE. However, inhibition of catalytic activity of SR-PDE by Zn 2+ is not surprising since this divalent cation produced a substantial decrease in affinity for cGMP (Figure 11 ), probably by altering topography at the catalytic site of SR-PDE. Additional binding studies, especially using purified SR-PDE, are required to more completely understand the precise relations among the [ 3 H]LY186126 binding site, the catalytic site of SR-PDE, and the divalent metal ion activation site.
In summary, a single class of high affinity binding sites for [ 
